ASCO 2022: Amivantamab-vmjw Under Study in NSCLC With Primary MET Exon 14 Skipping Mutation

By: Joseph Fanelli
Posted: Friday, June 24, 2022

Treatment with amivantamab-vmjw appears to demonstrate antitumor activity after MET inhibitor therapy in patients who have non–small cell lung cancer (NSCLC) with primary MET exon 14 skipping mutation, according to results of the phase I CHRYSALIS trial, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9008). Amivantamab is a fully human bispecific antibody targeting EGFR and MET. Enrollment for this trial is ongoing, said Matthew Krebs, PhD, of The University of Manchester and the Christie National Health Service Foundation Trust, United Kingdom, and colleagues.

In this study, the authors enrolled 43 patients with MET exon 14 skipping mutation NSCLC whose disease had progressed or who declined the current standard-of-care therapy. All patients were treated with 1,050 mg or 1,400 mg per week of amivantamab for one cycle, and biweekly thereafter. Of the group, 6 patients had no prior treatment, 11 had no prior treatment with a MET inhibitor, and 19 had received a prior MET inhibitor.

For the entire patient cohort, the overall response rate was 33%, with a 50% rate among treatment-naive patients, 46% for those with no prior MET inhibitor, and 21% in patients with prior MET inhibitor therapy. The clinical benefit rate was more than 54% for all patients, regardless of their prior treatment status.

The median duration of response was not reached, whereas 67% of patients experienced a duration of response of at least 6 months or more. The safety profile of the treatment was consistent with previously reported experiences with amivantamab, and treatment-related adverse events resulted in dose reductions or discontinuation in three patients each.

Disclosure: For full disclosures of the study authors, visit meetings.asco.org.

2022 ASCO Annual Meeting

---